Prognosis of Heart Failure with Reduced Ejection Fraction (HFrEF)
The prognosis of HFrEF remains poor despite modern therapies, with a 5-year survival rate of only 25% after hospitalization, though outcomes vary substantially based on ejection fraction trajectory, comorbidity burden, and recent worsening events 1.
Mortality and Survival Rates
The overall disease carries substantial mortality risk. Even with contemporary guideline-directed medical therapy (GDMT), patients face high rates of death and hospitalization 1. However, prognosis is not uniform across all HFrEF patients—it depends critically on several modifiable and non-modifiable factors.
Key Prognostic Determinants
Ejection Fraction Trajectory and Severity
Patients whose EF improves by ≥10% (HFrecEF) have dramatically better outcomes compared to those with persistent HFrEF, with lower mortality (106 vs. 164 events per 1000 patient-years), fewer hospitalizations (300 vs. 428 per 1000 patient-years), and reduced need for advanced therapies 2. Approximately 37.6% of HFrEF patients experience this degree of EF recovery 2.
Conversely, patients with EF <25% face significantly higher mortality (15%) and readmission rates (29%) compared to those with higher EF values within the HFrEF spectrum 3.
Recent Worsening Heart Failure Events
The presence of a recent worsening heart failure event (emergency department visit or hospitalization within 12 months) more than doubles mortality risk (HR 2.30,95% CI 2.01-2.63) and increases both all-cause hospitalization (HR 1.56) and HF hospitalization (HR 1.59) through 5 years 4. This affects 73% of HFrEF patients in real-world practice 4.
These patients present with more advanced disease, lower ejection fractions, greater comorbidity burden, and more echocardiographic evidence of cardiac dysfunction despite higher utilization of GDMT 4.
Comorbidity Burden
Multimorbidity directly worsens prognosis independent of cardiac function. Both cardiovascular comorbidities (HR 1.106, p=0.006) and non-cardiovascular comorbidities (HR 1.564, p<0.001) independently predict long-term mortality 5.
Patients with ≥6 comorbidities experience 59.5% mortality at 30 months compared to only 7.9% in those with 0-1 comorbidities 6. Over 50% of HFrEF patients have at least 4 concurrent comorbidities 6.
Comorbidities also indirectly worsen outcomes by limiting tolerance of GDMT, increasing myocardial stress (reflected in higher BNP and troponin levels), and reducing treatment intensity 5.
Echocardiographic Markers
Beyond ejection fraction alone, several structural parameters predict adverse outcomes:
- Pulmonary artery systolic pressure (PASP) >40 mmHg independently predicts readmissions 3
- Right ventricular dysfunction associates with worse outcomes 3
- Moderate-to-severe mitral regurgitation (present in 33% of patients) correlates with adverse events 3
- LV dilatation (present in 64%) and diastolic dysfunction (80%) are common 3
Demographic Factors
Female patients demonstrate better prognosis than males (adjusted HR 0.94, p<0.05), with lower mortality risk even after adjusting for age, comorbidities, medications, and EF trajectory 2. Women are also more likely to experience EF recovery (adjusted OR 1.66) 2.
Younger age predicts higher likelihood of EF improvement (OR 1.16 per decade younger) 2.
Clinical Implications for Risk Stratification
When assessing prognosis in an individual HFrEF patient, prioritize:
- Recent decompensation history (within 12 months)—this is the strongest modifiable risk factor
- Absolute EF value and trajectory—serial measurements matter more than single values
- Comorbidity count and type—both cardiac and non-cardiac
- Comprehensive echocardiographic assessment—not just EF, but PASP, RV function, and valvular disease
- Sex and age—younger females have best prognosis
Common Pitfalls
- Assuming all HFrEF patients have equivalent prognosis—the spectrum ranges from 8% to 60% mortality at 30 months depending on risk factors 6
- Focusing solely on EF—structural parameters, comorbidities, and recent events are equally important
- Single EF measurement—trajectory over time provides critical prognostic information 2
- Underestimating impact of non-cardiac comorbidities—these independently predict mortality and limit therapeutic options 5
Despite advances in therapy including SGLT2 inhibitors, ARNIs, and device therapies, substantial residual risk persists even with optimal quadruple GDMT 7, underscoring the continued need for aggressive risk factor modification, early intervention, and consideration of advanced therapies in high-risk patients.